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Abstract
Affinity chromatography has become an important tool for characterizing biomolecular interactions. The use of
affinity microcolumns, which contain immobilized binding agents and have volumes in the mid-to-low microliter range, has received particular attention in recent years. Potential advantages of affinity microcolumns include the many analysis and detection formats that can be used with these columns, as well as the need for only
small amounts of supports and immobilized binding agents. This review examines how affinity microcolumns
have been used to examine biomolecular interactions. Both capillary-based microcolumns and short microcolumns are considered. The use of affinity microcolumns with zonal elution and frontal analysis methods are discussed. The techniques of peak decay analysis, ultrafast affinity extraction, split-peak analysis, and band-broadening studies are also explored. The principles of these methods are examined and various applications are
provided to illustrate the use of these methods with affinity microcolumns. It is shown how these techniques
can be utilized to provide information on the binding strength and kinetics of an interaction, as well as on the
number and types of binding sites. It is further demonstrated how information on competition or displacement
effects can be obtained by these methods.
Keywords: Affinity microcolumns, High-performance affinity chromatography, Biointeraction analysis, Zonal
elution, Frontal affinity chromatography, Ultrafast affinity extraction
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1. Introduction

1.1. Basic principles of affinity chromatography and
HPAC

Biomolecular interactions make up an important component of the many pathways and responses that are present in
living systems. These interactions include the binding of substrates and co-factors to enzymes, antigens to antibodies, proteins to proteins, and sugars to lectins, as well as the binding
of small molecules such as hormones and drugs with transport proteins and receptors [1–4]. These interactions can determine the eventual activity, distribution, excretion, metabolism,
and effects of a solute or biomolecule in the body. In addition,
the binding of small molecules with proteins can determine
the solubility of hydrophobic compounds and can be an important source of direct or indirect competition between different solutes with the same binding protein (e.g., drug–drug
interactions) [5–12].
Various techniques can be employed for examining biomolecular interactions. These methods include X-ray crystallography, fluorescence spectroscopy, absorption spectroscopy, ultrafiltration, equilibrium dialysis, capillary
electrophoresis, surface plasmon resonance (SPR), and nuclear magnetic resonance spectroscopy (NMR) [5, 6, 10, 13–
27]. Two other, related methods that have seen increasing use
in the study of biomolecular interactions are affinity chromatography and high-performance affinity chromatography
(HPAC, also known as high-performance liquid affinity chromatography or HPLAC) [1–4, 9, 11, 28–30]. These methods
use a chromatographic column and support that contain an
immobilized biologically related agent (e.g., a protein or receptor) as the stationary phase. This immobilized agent can
then be used to study the binding of injected compounds to
the column or as a probe to examine the interaction of an injected compound with another binding agent in the mobile
phase [2, 3]. Various types of columns and formats can be
used in these experiments [1–3, 9, 11, 31–33]. However, one
topic that has been of growing interest in the analysis of biomolecular interactions is the use of affinity microcolumns for
such work (i.e., columns containing affinity ligands and with
volumes in the mid-to-low microliter range) [1, 2, 34–39].
This review examines the developments and applications that have appeared in the use of affinity microcolumns
as related to the characterization of biomolecular interactions. First, the basic principles behind affinity chromatography and HPAC are described, especially as related to the use
of these methods in investigating biomolecular interactions.
The general types of affinity microcolumns that have been
reported for binding studies are next considered. These microcolumns range from open-tubular capillaries and packed
capillaries to small columns based on monoliths or particulate supports [2, 4, 40–55]. The various approaches that have
been used with affinity microcolumns for binding studies are then discussed. This discussion includes various formats based on zonal elution and frontal analysis [1, 2, 11, 31,
34, 50–59]. In addition, techniques such as peak decay analysis, split-peak analysis, ultrafast affinity extraction, and
band-broadening measurements are discussed [2, 11, 31, 34,
55]. The principles behind each method are described, along
with the advantages and possible limitations of these methods. Various examples are also provided to illustrate the use
of these techniques with affinity microcolumns. These examples range from drug–protein interactions (including those
involving chiral drugs), to antibody–antigen interactions, the
binding of enzymes with inhibitors, and the interactions of
lectins with sugars, among others.
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Affinity chromatography is a liquid chromatographic technique that uses a biologically related binding agent, or “affinity ligand”, as the stationary phase to separate or analyze
sample components [3, 60–64]. This stationary phase can be
created by covalently attaching, entrapping, absorbing or in
some other way immobilizing the affinity ligand to a chromatographic support [3, 60, 61]. This solid support and the stationary phase are placed within a column or capillary that can
then be used for the purification, separation or analysis of targets capable of binding to the affinity ligand [28, 61–70]. The
retention and separation of a target from other sample components is based on the specific and reversible interactions that
characterize many biological interactions, such as the binding
of an antibody with an antigen or a hormone with a receptor
[1–3, 61–64]. If the interaction is strong (i.e., with an association equilibrium constant greater than 105–106 M−1), an elution
buffer and a change in the pH, temperature, or mobile phase
composition may be required to remove the target from the
column [34, 71, 72]. If weaker binding is present (i.e., an association equilibrium constant of 105–106 M−1 or less), it may be
possible to elute the target under isocratic conditions. This latter method is sometimes referred to as weak affinity chromatography (WAC) [29, 30]. The variety of elution formats, immobilized ligands, and columns that can be used in affinity
chromatography has made this method a valuable tool for the
study of biomolecular interactions [1–3, 31, 51, 57], as will be
discussed in this review.
In any type of affinity chromatography, the support that
is used for the immobilized affinity ligand should have low
non-specific binding to sample components and yet be easy
to modify for ligand attachment [60–64, 73–76]. Traditional affinity chromatography typically employs relatively inexpensive supports and non-rigid materials with low-to-moderate
efficiencies, such as agarose gels or other carbohydrate-based
materials [3, 62, 63, 73]. In the method of HPAC, which is the
type of affinity chromatography utilized with most affinity microcolumns, the support is a material that has sufficient mechanical stability and efficiency for use in HPLC [3, 9, 61, 64,
73, 74]. This type of support, in turn, tends to provide HPAC
with better speed and precision than traditional affinity chromatography, along with greater ease of automation through
the use of HPLC systems [1, 4, 59, 61, 73–76]. Possible supports
for HPAC include particulate materials based on modified silica or glass, azalactone beads, and hydroxylated polystyrene
media [1, 3, 61, 73, 74]. Various types of monolithic supports
have also been considered for use in HPAC and affinity chromatography, such as those based on organic polymers, silica
monoliths, cryogels and modified forms of agarose [4, 73, 75–
82]. The recent interest in monoliths for these affinity-based
separations is due to several useful features of these supports,
including their rapid mass transfer properties, low back pressures, and ability to be made in a variety of shapes and sizes
[4, 73, 75, 76, 79, 82].
The use of affinity chromatography and HPAC for the
study of biomolecular interactions is sometimes referred to as
analytical affinity chromatography, quantitative affinity chromatography, or biointeraction chromatography [2, 3, 11, 31,
51–59, 61, 83]. This type of approach either examines the interaction of an applied target with the immobilized affinity ligand or uses the affinity ligand to examine interactions of the
target with another binding agent in the mobile phase (see Fig-
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Figure 1. Two general schemes for the use of HPAC
and affinity chromatography to study biomolecular
interactions based on (a) the binding of an applied
target with the immobilized affinity ligand or (b) use
of the affinity ligand to examine interactions of the
target with another binding agent in solution.

ure 1) [2, 31, 61]. A great deal of information can be obtained
through such experiments. This information can include data
on the number of interaction sites for the target with a binding
agent, the equilibrium constants for this process, and the rate
of the interaction [2, 11, 31, 51, 55, 57, 61, 83, 84]. Data can also
be obtained on the types of competition the target may have
with other compounds for interactions with the binding agent,
and the structure and location of the sites that are involved in
these interactions [31, 57, 84]. The specific approaches that can
be used with affinity microcolumns to obtain this information
are described later in this review.

1.2. Types of affinity microcolumns
A reduction in column size has been of interest in the fields
of HPLC and chromatographic separations for many years.
This interest initially appeared due to some common limitations with traditional 10–25 cm × 4.6 mm i.d. HPLC columns,
such as issues related to high backpressures, solvent consumption, and difficulties in working with small sample volumes
[85]. To overcome these limitations, work began in the 1970s
to reduce the size of columns in chromatographic systems and
to produce various types of small-volume columns [86–89].
Examples of approaches that have been used specifically in
HPAC and affinity chromatography to produce affinity microcolumns are shown in Figure 2 [34–39].
The first approach for reducing the size of a chromatographic column is to decrease the column’s inner diameter, as
is illustrated in Figure 2(a). This change is usually accompanied by an increase in column length to maintain or provide
high efficiency for the system while still giving an overall decrease in volume versus traditional columns. This approach
may involve the use of either open-tubular capillary columns
or packed capillary columns [85]. Open-tubular capillaries
that have been used with affinity ligands for binding studies
have generally had an inner diameter of 100 μm and lengths
of 30–40 cm, giving total volumes of approximately 2–4 μL
[35–37]. Packed capillaries that have been used with affinity ligands and binding studies have had an inner diameter of up
to 0.5 mm and a length that ranges from 5 to 15 cm (volumes,
10–30 μL) [35–37, 41, 42, 46–49, 90–92].
There are several advantages to using the open-tubular or
packed capillary columns in affinity-based binding studies.
For instance, the flow rates applied to such columns are usually quite low (i.e., in the nL/min to μL/min range) and the
efficiencies can be high, resulting in a significant reduction in
mobile phase consumption and sample size requirements [85,
93]. One potential disadvantage is that these capillary columns
often require specialized equipment that is designed for work

at low flow rates and high efficiencies (e.g., microbore or nanoHPLC systems) [41, 43, 85, 93]. However, these columns are attractive for use with on-line detection by mass spectrometry,
which can provide high sensitivity in detecting small amounts
of targets and can be used to confirm the identity of a target in
a mixture of applied compounds [94–96].
Another approach for decreasing the column size is to reduce the length of the column, as shown in Figure 2(b). This
type of design can be employed in separations that do not
require high efficiencies, such as those based on simple adsorption/desorption mechanisms and selective binding for
affinity separations involving moderate-to-high strength interactions [3, 58, 60, 61, 97]. Various types of short microcolumns based on particulate supports or monolithic materials have been developed for affinity separations and
binding studies. These columns often have an inner diameter of 2.1 mm or smaller and lengths of 1–5 cm (i.e., volumes less than 35–175 μL). Other possible formats include affinity disks, with an inner diameter of 4.6 mm and lengths
of 1–2 mm [80, 98–100], or sandwich affinity microcolumns,
with effective lengths as small as 60–250 μm and volumes of
only 0.2–0.9 μL [101]. A few advantages of using these columns in binding studies are that they are easy to employ
with traditional HPLC systems, and they require only a small
amount of support and binding agent. This type of column is
often capable of withstanding high flow rates, because of its
low backpressure, and can provide sample residence times in
the second to millisecond range [38, 40, 102].
One advantage to utilizing either type of affinity microcolumn is that they are compatible with a variety of detection approaches. These detection forms include absorbance, fluorescence and near-infrared fluorescence, chemiluminescence,
matrix-assisted laser desorption/ionization mass spectrometry, and electrospray ionization mass spectrometry [35–42, 46–
49, 90, 102]. The small volume of affinity microcolumns [42,
43, 103] also leads to a significant decrease in the amount of
support and affinity ligand that are needed for binding studies when compared to more traditional affinity columns [80,
97, 101–104]. In a large number of cases, it is possible to reuse
the same binding agent for many experiments, which further
helps to improve the precision and to decrease the cost of this
method [50, 105, 106].

2. Zonal elution and affinity microcolumns
2.1. Principles of zonal elution
Zonal elution is one of the most common formats in HPAC
and affinity chromatography for studying biomolecular inter-
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Figure 2. Examples of affinity microcolumns that have been used for
studying biomolecular interactions,
including designs based on (a) opentubular or packed capillaries and
(b) short microcolumns or sandwich
microcolumns.

actions. This method was first used with affinity columns in
1974 [107] and is based on the measurement of peak retention
times, retention factors or peak profiles. This approach can be
used to provide information on the strength of binding by a
target with an affinity ligand and on the competition of the
target with other compounds for the binding agent [1–3, 11,
31, 51, 57, 108, 109]. In this type of experiment, a narrow plug
of the target is injected onto the affinity column under isocratic
conditions as a detector is used to monitor the elution time or
profile for the injected analyte. If relatively fast association and
dissociation kinetics are present on the time scale of the experiment, the retention time of the target should be directly related to the target’s strength of binding to the immobilized
agent and the amount of active binding agent that is present in
the column [2, 11, 30, 31, 109]. Factors that can be altered during zonal elution experiments include the mobile phase pH,
ionic strength and polarity, as well as the temperature, type
of target, type of affinity ligand in the column, and the presence of competing or displacing agents in the mobile phase. By
monitoring the changes in the retention for the target as these
conditions are varied, detailed data can be obtained on the nature of the interactions between the target and the immobilized binding agent [2, 11, 31, 66, 70, 109–111].
Figure 3(a) shows a typical zonal elution experiment in
which competition by a mobile phase additive causes a shift
in the retention of an injected target as these two compounds
compete for binding sites on an immobilized affinity ligand
[110]. This example shows the chromatograms generated
during injections of the site-selective probe R-warfarin onto
a 2 cm × 2.1 mm i.d. column (volume, 69 μL) that contained
the immobilized protein human serum albumin (HSA), with
the drug tolbutamide being placed into the mobile phase as a
competing agent. In this specific experiment, a decrease was
observed in the retention of R-warfarin as the concentration of
tolbutamide was increased, indicating that either direct competition or a negative allosteric effect was occurring between
these two compounds on HSA [110].
Another format in which zonal elution has been employed
with microcolumns is shown in Figure 3(b). In this case, the
immobilized binding agent is used to examine the binding of a
retained target with a second binding agent that is applied in
the mobile phase [112]. The column in this particular example
was 275 μL in volume and contained an immobilized form of

Figure 3. Examples of the use of zonal elution with affinity microcolumns in examining biomolecular interactions. In (a) competition
studies based on zonal elution were carried out using the injection of
R-warfarin as a site-specific probe onto a microcolumn containing immobilized human serum albumin (HSA) in the presence of various
concentrations of tolbutamide in the mobile phase. The results in (b)
show the elution profiles for retinoic acid receptor γ (RARγ) that was
applied to columns containing apo-cellular retinoic acid binding protein II (CRABP II) (open circles) or holo-CRABP II (black circles) and in
the presence of retinoic acid; the gray-shaded circles represent an elution profile of carbonic anhydrase II (CA II) applied to an apo-CRABP
II column. Adapted with permission from References [110] and [112].
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cellular retinoic acid binding protein (CRABP) that was initially
loaded with the target retinoic acid. A sample of a second possible binding agent for retinoic acid (i.e., retinoic acid receptor
isoform γ, or RARγ) was then applied to the column and examined for its elution profile. The presence of a shift in the elution
profile for this applied binding agent versus a control was used
to detect an interaction between RARγ and CRABP during the
transfer of retinoic acid between these binding agents [112].
One advantage of zonal elution is it requires only a small
amount of target for injection. This method can also examine
more than one compound in a sample provided there is adequate resolution between the peaks for these compounds or
a detection format is employed that can distinguish between
these eluting solutes [57]. As is illustrated in Figure 3(a and b),
it is also possible with zonal elution to obtain information on
site-specific interactions, on the competition of two targets for
the same binding agent [109, 113, 114] or on the competition of
two binding agents to the same target [115]. As will be demonstrated in the next few sections, this format can also provide
information on the strength of binding and the effects that
changes in the structure of a target or binding agent may have
on an interaction.

2.2. Estimating binding strength and retention using affinity microcolumns
Zonal elution can be used in a variety of ways to obtain information on biomolecular interactions. An important parameter to measure when describing these interactions is the degree or strength of binding that occurs in the system [11, 57,
116–126]. This information can be obtained from the retention
time or retention factor (k) for a target that is injected onto an
affinity column. This retention factor can be calculated from
the observed elution times through the following relationship,
k=

tR – tM
tM

(1)

where tR is the observed retention time for the injected target,
and tM is the column void time.
If relatively fast association/dissociation kinetics and linear
elution conditions are present during the measurement of the
retention factor (i.e., the apparent value of k is not affected by
the amount of injected sample or the flow rate), Equation (2) can
be used to relate this retention factor to the number of binding
sites for the target in the affinity column and to the association
equilibrium constants for the target at these sites [11, 31].
k=

(Ka1n1 + Ka2 n2 + … + Kannn)mL

(2)

VM

In this equation, the terms Ka1 through Kan represent the association equilibrium constants for the target at each of its binding sites in the column, n1 through nn are the fractions for each
type of site in the column, mL is the total moles of all binding
sites in the column, and VM is the void volume of the column.
The global association equilibrium constant (nKa) for the interaction of a target with the immobilized binding agent can
be obtained from the numerator of Equation (2), where nKa
is the summation of the terms Ka1n1 through Kannn. This term
is directly proportional to k if all of the binding sites have independent interactions with the target. If the target binds to
only one type of site on the affinity ligand and in the column,
the multisite equation in Equation (2) can be rearranged to the
simpler form that is provided in Equation (3),
k=

Ka mL
VM

(3)
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where Ka is the association equilibrium constant for the interaction, mL/VM represents the molar concentration of the binding sites for this interaction, and other terms are as defined
previously [11, 31].
A few recent studies have examined the ability of short affinity microcolumns to be used with zonal elution for estimates of retention factors and binding strength. One set of experiments was carried out at various flow rates for the drugs
carbamazepine and warfarin when applied to HSA affinity
microcolumns [116]. These columns contained 4.6 mm i.d. silica monoliths with lengths of 1–5 mm or were 4.6 mm i.d. columns that were 3 mm in length and that contained HSA immobilized to silica particles. It was found that similar retention
factors were obtained for warfarin on 3–5 mm long microcolumns, and for carbamazepine when the column length ranged
from 1 to 5 mm. These results indicated microcolumns as
short as 1–3 mm could be used to provide reproducible retention factors for drug–protein binding studies that involve systems with binding constants in the range of 103–106 M−1[116].
Additional work was carried out with racemic warfarin and ltryptophan on 2.1 mm i.d. HSA microcolumns that contained
silica particles and that ranged in length from 1 mm to 2 cm.
This report also indicated that columns as small as only a few
millimeters in length could be used for zonal elution studies of drug–protein binding for systems with affinities of 104–
106 M−1[103]. Some loss of precision in retention measurements
did occur with the use of these small columns and there was a
greater chance of column overloading [103, 116]. However, it
was noted that the latter effect could be dealt with by decreasing the sample load or by using reference compounds and retention ratios to adjust for shifts in the retention factors [103].
The fact that the retention factor is related both to the association equilibrium constants and number of binding sites for
an interaction can be used in a variety of ways. For instance, retention factor measurements of R- and S-propranolol, as model
drugs, have been used in examining the long-term stability of
affinity microcolumns that contained high-density lipoprotein
(HDL) and low-density lipoprotein (LDL) [117–119]. If an independent estimate is available for the binding capacity (mL), it
is possible to use this information with measured retention factors and Equations (2) or (3) to estimate the value of nKa for a
multi-site system, or Ka for a single-site interaction. This method
has been used to screen and compare the binding of several
site-selective probes and sulfonylurea drugs on microcolumns
containing entrapped samples of HSA or glycated HSA [120].
Zonal elution data (with detection based on mass spectrometry)
has been combined with binding capacities obtained by frontal
analysis on a packed capillary containing cyclin G-associated kinase for drug discovery; the results were then used to estimate
and rank the affinity of the kinase for a series of drug fragments
[123]. A similar method was used to rank the binding constants
for various drug fragments with the chaperone protein HSP90
(see Figure 4) [50] and for various carbohydrates in their binding to hen egg-white lysozyme [54]. It is also possible to use the
ratio of the retention factor to the known amount of binding
agent to provide an index that is related to nKa or Ka [126]. This
technique has been used to compare the activities and properties for proteins attached within organic-based monoliths that
were prepared under various polymerization conditions [100].

2.3. Competition and displacement studies using affinity microcolumns
Zonal elution and traditional HPAC or affinity columns
have often been employed in studying the competition and
displacement between drugs and other solutes during soluteprotein interactions [11, 31, 45, 57, 84]. In this type of experiment, a competing agent is placed at a fixed concentration in
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Figure 4. Use of zonal elution and mass spectrometry with a 0.5 mm i.d. × 10 cm packed
capillary containing the N-terminal domain of
the protein HSP90 to compare the relative retention of four drug fragments (four upper
chromatograms in each plot), using adenosine
(bottom chromatogram in each plot) as a reference. Adapted with permission from Reference [50].

the mobile phase. A small pulse of a target or site-selective
probe is then injected onto the column and allowed to interact
with the immobilized binding agent, as illustrated earlier in
Figure 3(a). As the target passes through the column, the competing agent may influence binding by the target to the affinity
ligand through direct competition or allosteric effects. When
these data are fit to the response that is predicted by various
models, the types of interactions that are occurring between
the target, competing agent and immobilized binding agent
can be determined. This, in turn, can provide information
on the number of interaction sites, the location of these sites
(i.e., through the use of site-selective probes), and the binding
strength at particular sites [31, 127–133].
To illustrate this process, Equation (4) shows the response
that would be expected between the retention factor for an injected solute and the concentration of a competing agent in the
mobile phase if these two solutes have direct competition at a
single type of site on an affinity column [11, 31, 57].
VM
1 Ka,IL VM [I]
=
+
k
Ka,AL mL
Ka,AL mL

(4)

In this equation, Ka,AL and Ka,IL are the association equilibrium constants for the interactions of the immobilized binding
agent (or affinity ligand, L) with the target/analyte (A) and
the competing agent (I) at their site of competition. This relationship predicts that a linear response with a positive slope
should be obtained for a plot of 1/k versus [I] if A and I have
a single site of competition. This relationship, in turn, can be
used to provide the value of Ka,IL for I at its site of competition with A. If no competition is present between A and I, this
type of plot will show only random variations in 1/k as [I] is
increased. If negative allosteric effects or multisite interactions
are present, deviations from a linear response at low concentrations of I should be obtained. If positive allosteric effects are
present, the value of 1/k should decrease as the concentration
of I is increased [31, 57].

Plots made according to Equation (4) have been used in
many recent studies involving affinity microcolumns. An example of a plot from a study that used a microcolumn containing HSA is shown in Figure 5(a)[110]. In this case, a linear response was obtained in a plot of 1/k for l-tryptophan as the
concentration of tolbutamide was varied in the mobile phase.
This result indicated that tolbutamide had direct competition
with l-tryptophan at Sudlow site II, the known binding site for
the latter compound with HSA. The same approach has been
employed with affinity microcolumns to investigate the competition of various probes with a number of other drugs during their interactions with the proteins HSA, glycated HSA,
and α1-acid glycoprotein (AGP) [44, 45, 109, 110, 113, 130–133].
Alternative forms of Equations (3) and (4) have been used
with other systems [51, 53, 84, 134]. One example was the use
of competitive zonal elution studies to examine the binding of
L-fucose, as a mobile phase additive, to immobilized Aleuria
aurantia lectin as injections of the oligosaccharide LNF III were
made as a probe [51].
Another type of graph that can be used to analyze both direct competition and allosteric effects using zonal elution data
is given in Figure 5(b). In this case, a plot of k 0/(k − k 0) versus
1/[I] is made according to Equation (5), where k 0 and k are
the retention factors for injected target A in the absence and
presence of the competing agent, respectively [135].
k0
1
=
×
k − k0 βI→A − 1

( K 1 [I] + 1 )

(5)

a,IL

This equation is based on a model where A and I may have
direct competition at a single site or allosteric interactions
through two different sites. If an allosteric effect is present,
the ability of A to bind to L is influenced by the binding of
I on L, which causes the association equilibrium constant for
A to change from Ka,AL to K′a,AL. This change can also be described by the coupling constant β I→A, which is equal to the
ratio K′a,AL/Ka,AL. A linear relationship obtained from this plot
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Figure 5. Results of zonal elution competition studies on HSA microcolumns examining the change in retention of (a) l-tryptophan as a
probe for Sudlow site II and (b) R-warfarin as a probe for Sudlow site
I in the presence of tolbutamide as a competing agent. The solid lines
show the best-fit responses that were obtained when fitting (a) Equation (4) or (b) Equation (5) to the data. These results were obtained under similar or identical conditions to those used in Figure 3(a). Reproduced with permission from Reference [110].

Figure 6. Chiral separations for (a) R- and S-warfarin and (b) d- and ltryptophan on a 4.6 mm i.d. × 10 mm microcolumn containing HSA
immobilized to a monolith based on a co-polymer of glycidyl methacrylate and ethylene glycol dimethacrylate. The mobile phase was
pH 7.4, 0.067 M phosphate buffer that contained 0.5% 1-propanol and
the flow rate was (a) 2.0 mL/min or (b) 3.0 mL/min. Reproduced with
permission from Reference [100].

can be used to determine the association equilibrium constant
for I with L (Ka,IL) and the coupling constant, βI→A. A value of
βI→A between 0 and 1 indicates that a negative allosteric effect
is present between A and I, while a positive allosteric effect is
indicated if βI→A is larger than 1. A unique advantage of this
method is that it can be used to look independently at both directions of an allosteric effect by changing which compound is
used as A or I in the experiment [135–137].
Plots made according to Equation (5) have been used in
various studies of biomolecular interactions based on affinity
microcolumns. Figure 5(b) is one example, which was used to
determine how binding by R-warfarin to HSA was affected by
tolbutamide as a competing agent. This plot was used to help
differentiate between allosteric effects and multi-site binding
during the interaction of these two solutes on an HSA microcolumn [110]. Equation (5) and similar plots have been utilized
with microcolumns to study the interactions between various
fatty acids and sulfonylureas with HSA or glycated HSA [138]
and allosteric effects that may occur on AGP as it binds to Spropranolol and warfarin [113].
Experiments based on competition studies and zonal elution can further be used to determine the location and structure of binding regions on proteins or other biomolecules. This
is done by using an injected probe compound that is known
to bind to a specific site on the protein or affinity ligand, with
the competing agent in the mobile phase being the compound
for which possible interactions at this site are being examined [31]. Such an experiment is illustrated by the examples
provided in Figure 5. With this technique it is possible to develop a model of both the number of binding regions a solute
may have with a protein, or other type of affinity ligand, and
the association equilibrium constants for the solute at each of

these sites. This technique has been used with microcolumns
containing HSA or modified forms of this protein to study the
interactions of drugs such as acetohexamide, tolbutamide, gliclazide, glibenclamide and imipramine at Sudlow sites I and II
or the digitoxin site of this protein [44, 45, 110, 130–133, 139].
The same method has been employed to look for common
binding regions of drugs and drug enantiomers on microcolumns that contained AGP [113].

2.4. Other applications of zonal elution with affinity
microcolumns
Another application of zonal elution is its use in examining
the effects of various conditions on binding of the target with
the affinity ligand. Conditions that can be altered during such
studies include the temperature, pH, ionic strength and content of the mobile phase [31, 66, 70, 111, 140–142]. For instance,
varying the polarity of the mobile phase can be used to alter
non-polar interactions between a target and a protein, and/or
change the conformation of the protein or the target. This is
a common tactic used with chiral stationary phases based on
proteins to alter their retention and stereoselectivity [40, 140,
141, 143]. Some examples are provided in Figure 6, in which
an organic modifier was used to increase the speed of chiral
separations for R/S-warfarin and d/l-tryptophan on a 4.6 mm
i.d. × 10 mm microcolumn that contained HSA immobilized to
an organic monolith [100].
It is also possible to use zonal elution to examine the effects
of changes in the structure of a target on its interactions with a
given binding agent. This general approach can involve creating a quantitative structure–retention relationship (QSRR), in
which the retention factors for a set of structurally related mol-
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ecules are measured on an affinity column under otherwise
similar temperature and mobile phase conditions. These data
are then compared to various factors that describe the structural components of the applied targets to see which of these
factors most affected the retention [35, 144–147]. This technique has been used with traditional HPAC columns to investigate the skin permeation of several organic molecules
through the use of a column containing immobilized keratin
[144], to characterize binding of HSA to benzodiazepine drugs
[145–147], and to examine the interactions of AGP with antihistamines, beta-adrenolytic drugs, and other agents [148–
154]. In work with affinity microcolumns, the same general
method has been used to compare the binding of various sulfonylurea drugs at both Sudlow sites I and II of HSA [155].
A related approach is to use affinity microcolumns to see
how biomolecular interactions change as variations are made
in the structure of the immobilized binding agent [156–158].
This tactic has been used to see how the non-enzymatic glycation of HSA, as occurs during diabetes [129, 159], may alter
the binding of this protein to various drugs and solutes. These
studies have used R-warfarin, l-tryptophan and digitoxin as
probes (i.e., for Sudlow sites I and II and the digitoxin site of
HSA, respectively), along with samples of glycated HSA that
had various known levels of modification. The results for in
vitro glycated samples indicated that changes in the affinities
for sulfonylurea drugs and l-tryptophan did occur as the level
of glycation for HSA was increased and that these changes
differed between solutes and the binding site that was examined [45, 110, 130–133]. Similar effects were seen in affinity microcolumns that contained in vivo glycated HSA that was obtained from several patients with diabetes [44].
Affinity microcolumns and zonal elution have also been
used in the high-throughput screening of compound fragment
mixtures based on WAC and mass spectrometry (WAC-MS).
This method has been utilized to screen the binding of drugs
to albumin [32] and binding of compound fragments to protease [52, 160] or kinase targets [123]. As an example, one recent
study showed that 111 fragments could be screened on a capillary column containing the protein HSP90, as illustrated earlier in Figure 4. The results of WAC were found to show good
agreement with data obtained by NMR, SPR, and isothermal
titration calorimetry, as well as crystallographic data [50].

There are several advantages, and potential disadvantages,
to using frontal analysis versus zonal elution to examine a biomolecular interaction. For instance, frontal analysis is easier to
use in providing independent information on both the overall number of binding sites for an interaction and the equilibrium constants for these interactions [11, 31]. On the other
hand, zonal elution competition experiments, as discussed in
the previous section, are more convenient for identifying interaction sites and measuring binding constants specifically at
these sites. Frontal analysis tends to require more solute than
zonal elution, but column overloading effects are not a problem in frontal analysis because column saturation is actually a
desirable feature for at least part of such an experiment [31]. In
addition, the higher amounts of a target that are typically used
in frontal analysis can make it easier to detect an interaction
with this method than when using zonal elution [31, 46, 90].

of

3.2. Estimating binding strength and number of sites using affinity microcolumns
An important application of frontal analysis is the use of this
approach to obtain information on both the overall number
of interaction sites an applied target has with an immobilized
affinity ligand and the equilibrium constants for these interactions. Data can be obtained for this purpose by applying to
the affinity column a wide range of target concentrations, as
demonstrated earlier in Figure 7(a). The mean position of the
breakthrough curve is then measured at each applied concentration of the target, and the resulting data are fit to various binding models, as illustrated in Figure 7(b) [117]. For

3. Frontal analysis and affinity microcolumns
3.1. Principles of frontal analysis
Frontal analysis, or frontal affinity chromatography (FAC), is
another common technique that is used in HPAC and affinity chromatography to study biomolecular interactions. In this
method, a target solution is continuously applied to a column
while the amount of target that elutes from the end of the column is monitored [57, 109, 161]. As the target binds to the immobilized affinity ligand, the column begins to become saturated and the amount of the target that elutes from the column
increases with time or with the volume of applied target [31].
The result is the formation of a breakthrough curve, as is illustrated in Figure 7(a) for R-propranolol that was applied to an affinity microcolumn containing HDL as the binding agent [117].
Frontal analysis was first used with traditional affinity columns in the mid-to-late 1970s [162–164]. In the early 1990s
this technique was used with HPAC to study drug–protein binding [165]. Over the last 10–15 years, this method has
been utilized with various types of affinity microcolumns and
capillary columns for binding studies; this includes the combination of this method with mass spectrometry, giving a
method known as frontal affinity chromatography–mass spectrometry (or FAC-MS) [46, 90–92, 117, 166].

Figure 7. (a) Typical chromatograms (i.e., breakthrough curves) obtained for a frontal analysis experiment, as obtained here for the application of various solutions R-propranolol to a 5 cm × 2.1 mm i.d.
column containing immobilized high-density lipoprotein (HDL). (b)
Analysis of frontal analysis data obtained for R-propranolol on the
HDL column by fitting to the results to a model based on a combination of a saturable binding site and a non-saturable interaction. Reproduced with permission from Reference [117].
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Table 1. Effect of column length on the association equilibrium constants (Ka) and binding capacities (mL) measured by frontal analysis for warfarin on affinity microcolumns containing immobilized human serum albumin.a
Column length (mm)

Column volume (μL)

20
10
5
3
2
1

69
35
17
10
6.9
3.5

mL (nmol)
27.6 (±0.2)
9.7 (±0.2)
4.1 (±0.3)
3.8 (±0.3)
2.6 (±0.3)
1.2 (±0.1)

Ka (×105 M−1)

Relative activityb

2.0 (±0.1)
3.0 (±0.1)
3.4 (±0.3)
2.3 (±0.1)
2.1 (±0.2)
2.6 (±0.8)

1.00 (reference)
0.68 (±0.02)
0.58 (±0.05)
0.92 (±0.08)
0.92 (±0.08)
0.83 (±0.08)

a. The inner diameter of all the columns was 2.1 mm. The Ka and mL values provided are the average results obtained over flow rates ranging from
0.5 or 1.0 to 2.0 mL/min. The results in this table are based on data provided in Reference [103].
b. The relative activities were determined by comparing the specific activity measured for each column to the specific activity measured for the
2 cm long column.

instance, either Equation (6) or (7) can be used to describe a
system in which a single-site interaction is occurring between
the target and the immobilized binding agent [31].
mL,app =

mL Ka[A]
1 + Ka[A]

1
1
+ 1
=
mL,app
KamL[A]
mL

(6)
(7)

In these equations, mL,app is the apparent moles of target that is
required to reach the mean position of the breakthrough curve
at a given concentration of the applied target or analyte ([A]).
The term Ka is the association equilibrium constant for this
process, and mL is the total moles of active binding sites that
are involved in this interaction. By using a non-linear fit of
mL,app versus [A] to Equation (6), or a linear fit of 1/mL,app versus 1/[A] to Equation (7), the values of both Ka and mL can be
obtained for this system. If multiple types of binding sites or
interactions are present, alternative binding models and equations can also be fit to the data [31, 167, 168].
An example of this type of analysis when using an affinity
microcolumn is provided in Figure 7(b). This example shows
the use of a model based on both a saturable binding site and a
non-saturable interaction to describe the interactions of R-propranolol with HDL [117]. This approach has been employed
with small columns in HPAC and with other drugs and serum
agents, such as the binding of S-propranolol and verapamil
with HDL [117], the interactions of R- and S-propranolol with
LDL [118], the binding of drugs with AGP [113, 169–173], and
the interactions of various drugs and solutes with HSA or
modified HSA [44, 45, 108, 110, 130–133, 139]. Frontal analysis was used to determine the binding capacity of adenosine
on a packed capillary containing cyclin G-associated kinase
[123], and FAC-MS has been used with open-tubular capillaries containing peroxisome proliferator-activated receptors to compare and rank the binding of the agents to various
urediofibrate-like dual agonists [36]. Capillary monolith columns containing lectins or enzymes have been employed with
FAC-MS to examine the equilibrium constants of applied targets with these affinity ligands [41, 46, 48]. FAC-MS has also
been coupled with capillary columns for the high throughput
screening of enzyme inhibitors, oligosaccharides, and other
targets for immobilized binding agents [166].
The effect of column size on the results of frontal analysis
experiments has been recently examined for systems with lowto-moderate affinity interactions [103]. This work used HSA as
the immobilized binding agent and warfarin as a model target (i.e., a drug with single-site binding to HSA and a wellcharacterized affinity for this site). Table 1 shows the results
that were obtained for 2.1 mm i.d. microcolumns with lengths
ranging from 2 cm down to only 1 mm and packed with silica particles. Each of these columns gave a good fit for their
frontal analysis data to a single-site model, and the measured
binding capacity decreased in proportion to the total column

volume. It was also found that all of these columns gave association equilibrium values that were in good agreement with
literature values; however, the results obtained for the short
columns did have less precision that those obtained for the
longer columns. The main benefit of using the shorter columns
was the much smaller amount of immobilized binding agent
that they required and their shorter residence times. These features made these affinity microcolumns appealing for future
use in the high-throughput screening of drug candidates and
in rapid studies of drug-protein binding [103].

3.3. Competition and displacement studies using affinity microcolumns
Frontal analysis, and especially FAC-MS, has also been used to
examine the competition between potential targets and immobilized binding agents on affinity microcolumns [36, 37, 57]. In
this type of study, a competing agent is added with the target
in the mobile phase. The resulting chromatograms are then analyzed by measuring the change in breakthrough time or volume of the target as a function of the competing agent’s concentration (see Figure 8) [37]. Direct competition or negative
allosteric effects between the target and competing agent can
be detected when the breakthrough time decreases with an increase in the competing agent’s concentration. Alternatively,
positive allosteric effects can lead to a larger breakthrough
time for the target as the concentration of the competing agent
is increased [57].
It is possible to obtain a qualitative ranking of the strength
of displacing agents based on chromatograms like those in
Figure 8, but a quantitative analysis of such data is possible as
well. For instance, Equation (8) has been used to describe the

Figure 8. Example of a displacement experiment using frontal analysis and detection based on mass spectrometry. These chromatograms
show the effects of adding (B) vitexin, (C) naringenin, (D) apigenin, (E)
quercetin, (F) kaempferol, or (G) luteolin to a solution containing (A)
quercetin as the target and applied to a 30 cm × 100 μm i.d. open-tubular capillary column containing an immobilized form of the histone
decarboxylase SIRT6. Adapted with permission from Reference [37].
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interactions between a competing agent (I) and the target during such an experiment [36, 37, 174–176].

ployed to screen the binding of enzyme inhibitors, oligosaccharides and peptide libraries [49, 166, 175, 176]. For instance,
an open-tubular capillary containing an immobilized nuclear
receptor was used in FAC-MS to determine the relative affinities for a series of chiral fibrates with this receptor [35].

VR − Vmin =

P
(Kd,IL + [I])

(8)

In this expression, Kd,IL is the dissociation equilibrium constant
of the competing agent with the immobilized affinity ligand,
[I] is the concentration of the competing agent, VR is the breakthrough volume of the target, and Vmin is the breakthrough volume of the target when the interaction being examined is completely suppressed (i.e., as can be determined by running the
target with a high concentration of the competing agent). The
term P is the product of the number of active binding sites and
the term Kd,IL/Kd,AL, where Kd,AL is the dissociation equilibrium
constant for the target (or analyte) with the immobilized ligand.
Several reports have used Equation (8) or equivalent relationships in displacement studies based on FAC-MS and affinity microcolumns [36, 37]. The example in Figure 8 utilized
an open-tubular capillary that contained the histone deacetylase SIRT6. This column was used with FAC-MS to estimate
the dissociation equilibrium constants for several structurally
related flavonoids based on their ability to displace quercetin, a known inhibitor for SIRT6 [37]. Open-tubular capillaries
containing the ligand binding domains of peroxisome proliferator-activated receptors were employed in a similar manner
to examine the interactions and rank the affinities of ureidofibrate-like dual agonists with these columns [36].

3.4. Other applications of frontal analysis with affinity
microcolumns
As mentioned earlier, changes in factors such as the temperature or mobile phase can alter a biomolecular interaction. Like
zonal elution, frontal analysis can be employed to see how
such changes may alter an interaction. One advantage of using frontal analysis for this purpose is it can be used to independently examine how both the affinity and moles of binding
sites are affected by a change in the temperature or reaction
conditions [31, 143]. As an example, the effect of temperature
on the binding for R- and S-propranolol with HDL and LDL
has been studied using affinity microcolumns [117–119]. The
results showed that a change in temperature had little effect
on either the association equilibrium constants or the binding
capacities between these drugs and binding agents [117–119].
Frontal analysis has also been used to examine the binding
of solutes to modified proteins. This technique has been utilized to compare the binding of several solutes to HSA that
has been modified to various extents by glycation [44, 45, 130–
133]. Both the affinities and binding capacities for targets such
as warfarin, l-tryptophan and sulfonylurea drugs were considered in going from normal HSA to in vitro [45, 130–133] or
in vivo [44] samples of glycated HSA. Warfarin and l-tryptophan were found to bind to both sets of proteins through a single-site interaction [122, 131], but the sulfonylurea drugs interacted through a two-site model that involved a set of high and
low affinity sites [130]. The results indicated that the glycation
of HSA could affect the affinity of this protein for l-tryptophan and some of the sulfonylurea drugs, but no appreciable
change was noted for warfarin under modification conditions
similar to those seen in diabetes [44, 131].
Affinity microcolumns and frontal analysis have been
used in a growing number of reports for the high-throughput
screening of compound mixtures with regards to their binding
to biological ligands. This research has used FAC-MS to rank
and measure the binding of several applied compounds in a
single experiment, as demonstrated with columns that have
contained enzymes, antibodies, lectins or human estrogen receptor β [166]. FAC-MS and such columns have been em-
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4. Other methods for studying biomolecular
interactions using affinity microcolumns
4.1. Peak decay analysis
Peak decay analysis is a method for kinetic analysis that is particularly well-suited for use with affinity microcolumns [177–
180]. This method was first described in 1987 [177] and was
originally based on the application of a target to an immobilized binding agent, followed by the application of a high concentration of a competing agent to displace the retained analyte. This early work used a column containing the lectin
concanavalin A to determine the dissociation rate constant
for the sugar 4-methylumbelliferyl α-d-mannopyranoside
from this binding agent, with 4-methylumbelliferyl α-dgalactopyranoside acting as a competing agent to avoid rebinding by the target sugar during the elution process [177]. It
was shown in later work with weak-to-moderate affinity systems that a modified version of this method can be used in
which no competing agent is required [178–180].
In a typical peak decay experiment, the elution step is carried
out at a flow rate, column size and/or competing agent concentration that prevents the displaced analyte from rebinding to the
column [31, 177–180]. The flow rate, support material and column size also need to be selected to provide mass transfer between the flowing and stagnant regions of the mobile phase that
is faster than the rate of dissociation for the target from the immobilized binding agent. If these conditions are met, the resulting elution profile can be used to obtain the dissociation rate
constant for the target from the binding agent [31, 177].
Once the elution profile has been collected for the target, a
plot can be made of the logarithm of the peak response versus
time. If dissociation of the target from the immobilized binding agent is the rate-limiting step for elution and no rebinding
of the target occurs to the column, Equation (9) can be used to
determine the dissociation rate constant for the target from the
immobilized binding agent [31, 177].
dmEe
ln
= ln (mE0 kd) − kd t
(9)
dt

(

)

In this equation, the mE is the initial moles of target that were
0
bound to the column, mEe is the moles of the target that elute
in the mobile phase at time t, and kd is the dissociation rate
constant of the target from the immobilized binding agent.
Under the given conditions, Equation (9) predicts that there
should be a linear relationship between the natural logarithm
of the elution peak, ln(dmEe/dt), and the time allowed for target elution, t. The dissociation rate constant can then be obtained from the slope of the resulting curve [2, 31, 177].
An example of peak decay experiment is shown in Figure 9,
in which the dissociation of nortriptyline is examined by using
the peak decay method with an AGP microcolumn containing silica particles [180]. This particular example is based on a
non-competitive peak decay method, in which short microcolumns and high flow rates, rather than a competing agent, are
used to reduce the possibility of a target rebinding to the column. This method has recently been modified for use with affinity microcolumns containing silica monoliths to study the
dissociation rates for a large set of drugs (i.e., warfarin, diazepam, imipramine, acetohexamide, tolbutamide, amitriptyline, carboplatin, cisplatin, chloramphenicol, nortriptyline,
quinidine and verapamil) with HSA [173, 180]. This approach
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Figure 9. Typical results for a peak decay experiment, as obtained for
the injection of nortriptyline at flow rates of 5, 7 or 9 mL/min (from
right-to-left) on a 1 mm × 4.6 mm i.d. microcolumn containing immobilized AGP. This example includes the (a) elution profiles and (b) natural logarithm of these elution profiles for a 100 μL injection of 20 μM
nortriptyline. Reproduced with permission from Reference [180].

has also been applied with affinity microcolumns that contain
AGP to estimate the dissociation rate constants of this protein
for amitriptyline and lidocaine, as well as nortriptyline [180].
Another variation of the peak decay method occurs when
a change in a factor such as pH is used to cause release of the
target and to prevent rebinding of this target to the column.
For example, this method was used to determine the dissociation rate constants of the herbicide 2,4-dichlorophenoxyacetic acid (2,4-d), and related solutes, from immobilized antibodies at various pH values and flow rates. This information was
then used to help in the design and optimization of an HPAC
system for the analysis of 2,4-d and related herbicides in water
samples [179]. The peak decay method has also been utilized
to study the elution kinetics of thyroxine from columns containing immobilized antibodies or aptamers [181] and to examine the dissociation of immunoglobulin G-class antibodies
from protein G (i.e., an antibody-binding protein) [113].

4.2. Ultrafast affinity extraction
Another method for examining biomolecular interactions and
using microcolumns is ultrafast affinity extraction [38, 39, 80,
101, 102, 104, 182]. This approach examines the interaction of
a target and a binding agent that is in solution but uses an affinity microcolumn to probe the non-bound, or free, fraction
of the target that remains. In this technique, the target is injected in the presence or absence of the soluble binding agent
onto a microcolumn that contains an affinity ligand that can
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selectively retain the target in its free form. This affinity ligand
may be a specific agent, such as an antibody for a given target
[80, 101, 182]. Alternatively, the affinity ligand may be a more
general binding agent, such as a serum transport protein like
HSA for the retention of various drugs [38, 39, 102, 104]. If the
flow rate and column conditions are selected correctly, the residence time for the sample in the column can be made small
enough that no significant dissociation will occur of the target
from the soluble binding agent as the sample passes through
the column. For instance, affinity microcolumns have been
used to produce sample residence times down to the low-tomid millisecond range for this method [38, 40, 104].
This type of study is carried out by using the general
scheme shown in Figure 10, in which an affinity microcolumn containing HSA is used to separate the free and proteinbound fractions of a drug or small target in a sample [38]. In
this example, the protein-bound fraction of the target and the
protein in the sample will elute first in the non-retained fraction. This is followed later by elution of the retained free fraction of the target. The free fraction of the target can then be
determined by comparing the measuring retained peaks for
the target in the presence or absence of the soluble binding
agent. This information, in turn, can be used to determine the
association equilibrium constant for the interaction of the target with the binding agent in the sample if the binding agent’s
total concentration is also known. For instance, Equations
(10) and (11) describe the relationship between the observed
free fraction (f) and the association equilibrium constant (Ka)
for a target (A) and soluble binding agent (P) that have a single-site interaction.
f=
Ka =

CA − [A − P]
CA

[A − P]
(CA − [A − P]) (CP − [A − P])

(10)
(11)

In these equations, CA is the total concentration of the target
in the original sample, CP is the total concentration of soluble
binding agent, and [A – P] is the concentration of the targetbinding agent complex in the original sample [38, 40].
One advantage of free fraction analysis is its ability for
rapid measurements. This is partly due to the fact that sample residence times in the range of only a few hundred milliseconds or less are used to minimize the possibility that the
target may dissociate from the soluble binding agent during
the analysis [38, 40, 104]. It has been shown that the results obtained by this technique are comparable to those found with
the reference methods such as ultrafiltration and equilibrium
dialysis, among others [38–40, 57, 182]. Furthermore, because
this method directly examines the interactions between a target and a soluble binding agent, it is not subject to the immobilization effects that can occur with other affinity methods if
improper conditions are used to couple the binding agent to
the support [38, 39, 80, 101, 102, 104, 182].

Figure 10. General scheme for the use of ultrafast affinity extraction with an HSA microcolumn to separate the free and protein-bound fractions of
a drug or solute in an injected sample. Reproduced with permission from Reference [38].
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Several recent studies have used ultrafast affinity extraction
to examine biomolecular interactions. For instance, this method
has been used with immobilized antibodies and fluorescence
detection to measure the free drug fraction in mixtures of warfarin and HSA [104]. This technique has also been combined
with a displacement immunoassay to measure the free fraction
of thyroxine and phenytoin in clinical samples by using chemiluminescence or near-infrared fluorescence detection [39, 102,
182]. Use of this scheme to estimate association equilibrium constants has been shown with HSA and drugs such as R- or S-warfarin, S-ibuprofen and imipramine to give good agreement with
the values obtained by other methods [38]. In a recent study, a
multi-dimensional HPAC system was developed by combining
ultrafast affinity extraction with a chiral stationary phase to simultaneously examine the free fraction of warfarin enantiomers
in serum or drug–protein mixtures. The binding constants that
were estimated for R- and S-warfarin with HSA or serum by
this approach also gave results comparable to those of a reference method and literature values [40].

4.3. Split-peak analysis
The split-peak method is another technique that is readily
employed with affinity microcolumns. This is a method of kinetic analysis that is based on the fact that there is a probability during a chromatographic separation that a small fraction
of target will elute non-retained from the column without interacting with the stationary phase. In HPAC, this method can
be used to study the rate of association of a target with an immobilized binding agent by using column size and flow rate
conditions that promote the probability of this effect [97].
The following equation describes how the relative size of the
non-retained target fraction ( f ) will change with the flow rate
when a small amount of target is injected onto such a column [97].
−

(

1
1
1
=F
+
ln f
k1Ve kamL

)

(12)

In Equation (12), F is the flow rate, mL is the moles of active and
immobilized binding agent in the column, and Ve is the excluded
volume (i.e., the volume of flow mobile phase) in the column.
The term k1 is the forward mass transfer rate constant for the target as it moves from the flow mobile phase region to the stagnant
mobile phase at the surface or within the pores of the support,
and ka is the association rate constant for the target as it binds to
the affinity ligand in the column. This equation shows that the
rate-limiting step in the binding of the target to the column can
be either mass transfer in the mobile phase, as represented by the
term 1/(k1Ve), or adsorption to the affinity ligand, as represented
by 1/(kamL). Thus, information can be obtained on the interaction
of the target with the affinity ligand if the term 1/(kamL) is made
comparable to or larger than 1/(k1Ve) [97].
The results for a typical series of split-peak experiments are
shown in Figure 11 [97]. As part of this process, the peak areas for the retained and non-retained fractions of an injected
target are first made over a range of flow rates and at various sample concentrations. A plot of −1/ln(f) versus F is then
made according to Equation (12) at each sample concentration,
and the measured slopes are extrapolated to an infinitely dilute sample [97, 183, 184]. This slope is then compared to independent estimates of the mass transfer contribution, 1/(k1Ve),
by injecting the same analyte on an inert control column or on
a column with rapid association kinetics. If a separate estimate
of mL is also available, this process allows 1/(kamL) and ka to be
obtained [97]. A key advantage of this approach is it requires
only peak area measurements. The main disadvantage is this
method tends to be limited to targets and binding agents with
relatively slow dissociation kinetics, which generally corresponds with high affinity interactions [2, 97].
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Figure 11. Analysis of split-peak data according to Equation (12) for
injections of rabbit immunoglobulin G (IgG) onto protein A columns
prepared by various immobilization methods and supports. The conditions for each plot were as follows: Schiff base method, 500 Å pore
size silica, 22 μg IgG (○); Schiff base method, 500 Å pore size support,
11 μg IgG (●); Schiff base method, 50 Å pore size support, 15 μg IgG
(▲); carbonyldiimidazole method, 500 Å pore size support, 2.7 μg IgG
(■); and ester/amide method, 500 Å pore size support, 8.2 μg IgG (♦).
Reproduced with permission from Reference [97].

Several applications have appeared for the split-peak method
using affinity microcolumns. For instance, this technique was
originally used to study and compare the binding kinetics of
rabbit immunoglobulin G (IgG) on various columns containing protein A that was immobilized by different methods (see
Figure 11) [97]. Based on this data it was possible to obtain
the association rate constant for IgG with each protein A support [97, 183], which later made it possible to optimize and use
one of these supports for the analysis of human IgG in clinical samples [185]. This method has also been utilized to determine the apparent association rate constants for IgG on columns containing only protein A or protein G, or a mixture of
these two antibody-binding agents [184].
A modified form of the split-peak method has been reported for the case where there is non-linear elution and an
adsorption-limited rate for target retention [184, 186–190].
This modified approach has been used to examine the association kinetics of HSA with a variety of antibody-based systems [188–190]. In addition, this non-linear method has been
utilized to help model and describe the behavior of chromatographic-based competitive binding immunoassays [186, 191,
192]. Recent work has also expanded this method for use in
a frontal analysis format to examine the binding of herbicides
with immobilized antibodies [179] and thyroxine with immobilized antibodies or aptamers for this hormone [181].

4.4. Band-broadening studies and peak profiling
There are several methods for studying the kinetics of a biomolecular interaction based on the use of HPAC and affinity
chromatography [11]. For example, systems that have low-tomoderate strength interactions (i.e., Ka < 106 M−1) can be examined through the use of band-broadening measurements
[11, 31]. This technique, known as the plate height method, involves a measurement of the total plate height at several flow
rates for a target on a control column containing no binding
agent and on an affinity column that contains the immobilized binding agent of interest. These data are then used to determine the plate height contribution due to stationary phase
mass transfer (Hk). This term is of interest because it is related
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to the dissociation rate of the target’s interaction with the immobilized binding agent, as indicated by Equation (13).
Hk =

2uk
kd (1 + k)2

(13)

In Equation (13), u is the linear velocity of the mobile phase
in the column, k is the retention factor of the injected target,
and kd is the dissociation rate constant between the target and
immobilized binding agent. According to this relationship, a
plot of Hk versus (uk)/(1 + k)2 should give a linear relationship
with a slope that can provide the value of kd [31].
The plate height method has been applied with traditional
HPAC columns to study the association and dissociation kinetics of R/S-warfarin and d/l-tryptophan with HSA [121].
This method has also been used to examine the changes in
binding of R/S-warfarin and d/l-tryptophan that occur as a
result of the change in reaction conditions (e.g., pH, temperature, and organic modifier content of the mobile phase) [121].
Although this method has not been used directly with microcolumns, preliminary work with both silica particles and silica
monoliths indicates that plate height measurements suitable
for this type of work can be carried out by using 2.1 mm i.d.
columns as small as 1–5 mm in length [103, 116].
Peak profiling is a variation on this general scheme which
directly combines band-broadening data for a target on a control column and an affinity column, as determined under linear elution conditions. This method was first proposed in 1975
[193] and involves a determination of the retention times and
total plate heights on the affinity column for the target and a
non-retained solute (or for the target on a control column, in
the latter case). Such measurements have been made at a single flow rate to find the value of kd for the interaction of the
target with an immobilized binding agent, or these measurements can be made at multiple flow rates [44, 193–198].
One way that peak profiling data can be analyzed is according to Equation (14),
2uk
HR − HM =
= Hk
kd (1 + k) 2

(14)

where HR is the plate height for the target on the affinity column and HM is the plate height of the non-retained solute on
the same column, or for the target on an inert control column.
The other terms are the same as defined for Equation (13). It
is possible with this new relationship to either calculate the
value of kd at a single flow rate or to make a plot of (HR − HM)
versus (uk)/(1 + k) 2 for data obtained at several flow rates and
to use the slope of the resulting line to get kd [44]. Both Equations (13) and (14) are for a situation in which the target has
only a single type of interaction with the affinity column. Recently, an expanded set of equations have been described for
use with systems that have multi-site interactions with both
the support and an affinity ligand [198].
The peak profiling method has been applied to several
systems in recent studies. For instance, this method was
used to examine the dissociation rate of l-tryptophan from
immobilized HSA, giving a value for kd that was consistent with those obtained by other methods [195]. The multisite method for peak profiling has been used to determine
the dissociation rate constants for carbamazepine and imipramine with HSA (see Figure 12) [194]. A modified form of
this technique has also been employed to compare the dissociation rate constants of chiral metabolites for the drug phenytoin with HSA [194]. As work continues in the creation of
improved affinity microcolumns, including the use of capillaries [35, 36, 46–48, 92, 129] or monoliths [4, 73, 75, 76], it is
expected that peak profiling can also be applied to separations that employ such columns.

Figure 12. (a) Chromatograms obtained at several flow rates and (b)
analysis of the resulting band-broadening data according to Equation (14) for studies of the dissociation rate of carbamazepine from a
5 cm × 4.6 mm i.d. HSA column by the peak profiling method. Reproduced with permission from Reference [194].

5. Conclusions
This review discussed various methods based on affinity microcolumns for the study of biomolecular interactions. These
microcolumns, which have typical volumes in the mid-to-low
microliter range, contain an immobilized binding agent for
the selective retention of target compounds. In binding studies, these columns can be used to examine the target’s interaction with the immobilized binding agent or can use this
immobilized agent to probe interactions of the target with secondary binding agents in the mobile phase. Microcolumns can
be made by decreasing the inner diameter and increasing the
column length, as is used in affinity open-tubular capillaries
or packed capillaries (i.e., for separations requiring a high efficiency), or by reducing the length of the column (i.e., as can
be used in separations that do not require high efficiencies).
Either type of microcolumn can be employed with many detection formats and can lead to a significant decrease in the
amount of binding agent and support that are needed versus
traditional columns for affinity chromatography or HPAC.
Affinity microcolumns can be used in many formats and
can provide a wide range of information on biomolecular interactions. Two techniques that are commonly used in these
studies are zonal elution and frontal analysis. With these
methods, it is possible to determine the degree of binding
between a target and binding agent, to measure the equilibrium constant for this interaction, and to estimate the number
of binding sites. It is further possible to investigate the ability of a target to compete with other compounds and to look
at the effects of changing the reaction conditions, the structure
of the binding agent, or the type of target. Other methods that
have been used with affinity microcolumns include peak de-
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cay analysis, ultrafast affinity extraction and split-peak analysis. The possible use of band-broadening measurements and
peak profiling with affinity microcolumns was discussed as
well. These techniques can provide data on the association/
dissociation rates of a biomolecular interaction and can probe
the binding of a target with a soluble binding agent.
The potential advantages and versatility of affinity microcolumns make them attractive tools for biochemical analysis.
This is illustrated by the diverse group of applications that has
already been reported for affinity microcolumns in the analysis of biomolecular interactions. Applications that were described in this report included studies on the interactions of
pharmaceutical agents with serum proteins, the binding of antibodies with their targets and antibody proteins, the screening of libraries for potential enzyme inhibitors, and the binding of lectins with sugars. As further developments appear in
the design and use of affinity microcolumns, it is expected that
these columns and their associated techniques will continue to
grow in importance as means for examining biomolecular interactions in biomedical and pharmaceutical research.
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